Sheridan

Researchers are investigating the best way to use Selective Laser Trabeculoplasty (SLT) therapy for people with glaucoma or ocular hypertension. The study aims to find out if performing SLT at a low energy level is as effective as using the standard energy level. It also evaluates whether repeating low energy SLT once a year can better prevent or delay the need for daily eye drop medications compared to waiting until the effects of the initial SLT wear off before repeating the treatment. Participants will receive SLT treatments at either low energy or standard energy levels. The study compares these two approaches to see which is more effective over time. Some participants will have their low energy SLT repeated annually to assess if this schedule helps in managing their eye condition better than waiting for the treatment effects to diminish before repeating SLT. During the study, participants will be monitored for up to 48 months to track their survival without requiring daily eye drops, with primary outcome measures at 12 and 48 months. Researchers will check eye pressure and overall eye health regularly, ensuring safety and effectiveness of the treatments. Participants need to attend scheduled visits and follow study procedures throughout the study duration, which may include periodic eye exams and assessments.

To evaluate the safety and effectiveness of VisiPlate Aqueous Shunt to lower intraocular pressure (IOP) in subjects with open-angle glaucoma for whom medical and surgical treatments have failed.

HIV prevalence is high among transgender women in the United States, with about 14% affected. Researchers are evaluating a new bilingual digital shared decision-making tool called WePrEP, designed to help transgender women and their healthcare providers choose the best HIV prevention method, specifically between oral PrEP and injectable cabotegravir (CAB-LA). This tool aims to improve communication about PrEP options and address unique concerns such as interactions with gender-affirming hormones. WePrEP is accessible on providers' electronic devices and supports discussions during in-person or virtual visits. The study involves a randomized controlled trial with 69 transgender women and 6 PrEP service providers in the Denver area. Providers will use WePrEP with some participants to guide PrEP selection and adherence strategies, while others receive standard CDC recommendations. The study includes both English- and Spanish-speaking individuals and focuses on ensuring participants choose the ideal PrEP method. Participants will be assessed at enrollment for the feasibility and acceptability of WePrEP. The study will collect data through validated scales and qualitative methods to evaluate how well the tool supports communication and decision-making. The total participation time is not specified, but the study includes pilot testing and thorough usability assessments to inform future use and potential integration into healthcare systems.